QCOR News 88.16 06/09/2014 05:23:02 Questcor Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Questcor Pharmaceuticals (QCOR) 88.16 $QCOR

Shares of QCOR Up 29.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 05, 4:46PM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 29.45% as of today's recent price of $87.26.

Lannett Tops Trio Of Medical Small Cap Leaders
at Investor's Business Daily - Thu Jun 05, 7:02AM CDT
Small, fast-growing companies in hot industries, such as generics drugmaker Lannett, are good prospects for a stock watch list. Today's Screen Of The Day is Small Cap Leaders, highly rated companies with a market capitalization of $300 million to $2...

Pharma Stocks Review -- Research on Akorn, Questcor Pharma, Nektar Therapeutics, and Endocyte
PR Newswire - Thu Jun 05, 7:00AM CDT
On Wednesday, June 04, 2014, the NASDAQ Composite ended at 4,251.64, up 0.41%, the Dow Jones Industrial Average advanced 0.09%, to finish the day at 16,737.53, and the S&P 500 closed at 1,927.88, up 0.19%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, with the index also advancing 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Nektar Therapeutics (NASDAQ: NKTR) and Endocyte Inc. (NASDAQ: ECYT). Free technical research on AKRX, QCOR, NKTR and ECYT can be downloaded upon signing up at:

Questcor Provides Support to Lupus Foundation of America Awareness, Education and Advocacy Efforts
PR Newswire - Tue Jun 03, 9:28AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced its sponsorship of the Lupus Foundation of America's (LFA) eight national office Walk to End Lupus Now(TM) events and its support of a variety of Lupus Awareness Month activities.

FDA Approvals, Digital Health Guidance, Conference Presentations, and Recognitions - Analyst Notes on Intercept Pharmaceuticals, Cigna, Baxter, Questcor and Mallinckrodt
PR Newswire - Tue Jun 03, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Cigna Corporation (NYSE: CI), Baxter International Inc. (NYSE: BAX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Mallinckrodt PLC (NYSE: MNK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3242-100free.

SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.43% Gain
Comtex SmarTrend(R) - Mon Jun 02, 4:25PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $89.51 to a high of $92.38. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $90.50 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Shares of QCOR Up 31.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 29, 11:00AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 31.17% as of today's recent price of $88.42.

Kors, Qihoo Among 5 Top Stocks With 99 EPS Ratings
at Investor's Business Daily - Thu May 29, 7:02AM CDT
Michael Kors continued to show its dominance in the luxury-brand market, posting fourth-quarter earnings that topped analyst estimates Wednesday. The company is among highly rated firms that have strong long-term fundamentals. The Top Fundamentals...

Questcor Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.26%
Comtex SmarTrend(R) - Wed May 28, 5:39PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.75 to a high of $90.48. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.75 on volume of 702,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Questcor Receives "Recognition of Appreciation" Award from MS Views & News
PR Newswire - Wed May 28, 2:28PM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has been honored with a "Recognition of Appreciation" Award from MS Views & News, Inc., a leading multiple sclerosis (MS) education, information and advocacy organization.

Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...

3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 6:45PM CDT
The broader market may suffer through its tumultuous one- or two-day pullbacks now and then, but the fact that three-out-of-eight stocks are within 10% or less of a fresh 52-week high demonstrates how resilient this market has been. For skeptics like...

Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 38.4% (QCOR)
Comtex SmarTrend(R) - Thu May 22, 9:36AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 38.41% as of today's recent price of $93.30.

Senior Level Appointments, Collaboration Agreements, Prestigious Awards Nominations, and Company Updates - Analyst Notes on Biogen Idec, Questcor, Zimmer, Cigna and Ctrip.com
PR Newswire - Thu May 22, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Zimmer Holdings, Inc. (NYSE: ZMH), Cigna Corporation (NYSE: CI) and Ctrip.com International Ltd. (NASDAQ: CTRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2808-100free.

Downgrade Alert for Questcor Pharmaceuticals (QCOR)
Comtex SmarTrend(R) - Tue May 20, 6:56AM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $92.08 on volume of 2.0 million shares, below average daily volume of 3.5 million. Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company's primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions.

Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology
PR Newswire - Tue May 20, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Puma Biotechnology, Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2665-100free.

Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri May 16, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Questcor (QCOR) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 15, 8:00AM CDT
Questcor (QCOR) is Overbought: Is A Drop Coming?
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles